Single-Agent in Previously Untreated Unresectable Locally Advanced or Metastatic TNBC (ASCENT-03)
The safety of TRODELVY was evaluated in 275 patients with unresectable locally advanced or metastatic TNBC who had not received previous systemic therapy for advanced disease and who were not candidates for PD-1 or PD-L1 inhibitor therapy who had received at least one dose of TRODELVY 10 mg/kg in ASCENT-03. [see Clinical Studies (14.1)]. The median duration of treatment was 8.3 months (range: 0 to 29 months).
Serious adverse reactions occurred in 26% of patients receiving TRODELVY. Serious adverse reactions in > 2% of patients included diarrhea, febrile neutropenia, and neutropenia (3.6% each) and pneumonia (2.9%). Fatal adverse reactions occurred in 2.5% of patients who received TRODELVY including sepsis (1.1%) and acute respiratory failure , neutropenic colitis, pneumonia, and septic shock (0.4% each).
Permanent discontinuation of TRODELVY due to adverse reactions occurred in 3.6% of patients, of which interstitial lung disease accounted for 1.1%.
Dosage interruptions of TRODELVY occurred in 66% of patients. Adverse reactions which required dosage interruption in ≥ 5% of patients were decreased neutrophil count (43%), diarrhea (6%), decreased leukocyte count and COVID-19 (5% each).
Dose reductions of TRODELVY due to an adverse reaction occurred in 37% of patients. Adverse reaction which required dose reductions in >2% of patients included decreased neutrophil count (18%), diarrhea (6%), fatigue (4.7%), febrile neutropenia (2.5%), and weight decreased (2.2%).
The most common (≥25%) adverse reactions, including laboratory abnormalities, were decreased neutrophil count (84%), decreased leukocyte count (80%), decreased hemoglobin (78%), nausea (61%), diarrhea and alopecia (55% each), increased glucose (52%), decreased lymphocyte count and fatigue (47% each), increased alanine aminotransferase (39%), increased alkaline phosphatase and constipation (38% each), increased lactate dehydrogenase (35%), increased aspartate aminotransferase (31%), decreased potassium (28%) and vomiting (25%).
Tables 3 and 4 summarize the adverse reactions and laboratory abnormalities in ASCENT-03.
Table 3: Adverse Reactions in ≥ 10% of Patients with Metastatic TNBC in ASCENT-03 | TRODELVY (n=275) | Treatment of Physician’s Choice
(n=276) |
|---|
| Adverse Reaction
| All Grades (%) | Grade 3 - 4 (%) | All Grades (%) | Grade 3 - 4 (%) |
|---|
| Gastrointestinal disorders |
| Nausea | 61 | 1.8 | 34 | 0.4 |
| Diarrhea
| 55 | 10 | 20 | 0.7 |
| Constipation | 38 | 0 | 25 | 0 |
| Vomiting | 25 | 1.8 | 13 | 1.4 |
| Abdominal Pain
| 24 | 0.7 | 12 | 0 |
| Stomatitis
| 19 | 1.1 | 9 | 0.4 |
| Skin and subcutaneous tissue disorders |
| Alopecia | 55 | 0 | 27 | 0 |
| Rash
| 20 | 0.4 | 18 | 0.4 |
| Pruritus | 10 | 0 | 6 | 0 |
| General disorders and administration site conditions |
| Fatigue
| 47 | 3.3 | 47 | 4.0 |
| Edema
| 11 | 0.4 | 11 | 0 |
| Pyrexia
| 11 | 1.1 | 10 | 0.7 |
| Respiratory, thoracic and mediastinal disorders |
| Cough
| 18 | 0 | 13 | 0.4 |
| Metabolism and nutrition disorders |
| Decreased appetite | 17 | 0.7 | 10 | 0.4 |
| Nervous system disorders |
| Headache
| 17 | 0.4 | 12 | 0 |
| Peripheral neuropathy
| 12 | 0 | 31 | 0.4 |
| Infections and infestations |
| Upper respiratory tract infection
| 16 | 0.4 | 9 | 0 |
| Urinary tract infection
| 10 | 0.7 | 15 | 0.7 |
| Musculoskeletal and connective tissue disorders |
| Arthralgia
| 15 | 0 | 17 | 0.4 |
| Back pain | 11 | 0.4 | 8 | 0.4 |
Table 4: Laboratory Abnormalities in > 10% of Patients with Metastatic TNBC in ASCENT-03| Laboratory Abnormality | TRODELVY (n=275) | Treatment of Physician’s Choice (n=276) |
|---|
| All Grades (%) | Grade 3 - 4 (%) | All Grades (%) | Grade 3 - 4 (%) |
|---|
| Hematology | |
| Decreased neutrophil count | 84 | 47 | 80 | 43 |
| Decreased leukocyte count | 80 | 29 | 80 | 33 |
| Decreased hemoglobin | 78 | 7 | 81 | 19 |
| Decreased lymphocyte count | 47 | 16 | 53 | 19 |
| Decreased platelet count | 18 | 6 | 40 | 17 |
| Chemistry | |
| Increased glucose | 52 | 0 | 44 | 0 |
| Increased alanine aminotransferase | 39 | 4.0 | 56 | 6 |
| Increased alkaline phosphatase | 38 | 1.1 | 35 | 0 |
| Increased lactate dehydrogenase | 35 | 0 | 35 | 0 |
| Increased aspartate aminotransferase | 31 | 2.2 | 47 | 2.5 |
| Decreased potassium | 28 | 5 | 18 | 2.5 |
| Decreased albumin | 23 | 2.5 | 14 | 0.4 |
| Decreased magnesium | 19 | 2.9 | 25 | 0.7 |
| Decreased sodium | 18 | 1.5 | 15 | 1.1 |
| Increased phosphate | 16 | 0 | 9 | 0 |
| Increased potassium | 16 | 0.7 | 18 | 0.7 |
| Increased magnesium | 14 | 5 | 11 | 1.8 |
| Hypoglycemia | 14 | 1.1 | 9 | 0 |
| Decreased phosphate | 12 | 0 | 10 | 0 |
| Increased urate | 12 | 0 | 4 | 0 |
In Combination with Pembrolizumab in Previously Untreated, Unresectable Locally Advanced or Metastatic TNBC whose tumors express PD-L1 (ASCENT-04)
The safety of TRODELVY in combination with pembrolizumab was evaluated in 221 patients with unresectable locally advanced or metastatic TNBC who have not received previous systemic therapy for advanced disease and whose tumors express PD-L1 who received at least one dose of TRODELVY 10 mg/kg in combination with pembrolizumab. [see Clinical Studies (14.1)]. The median duration of treatment of TRODELVY was 8.9 months (range: 0 to 27 months).
Serious adverse reactions occurred in 38% of patients receiving TRODELVY in combination with pembrolizumab. Serious adverse reactions in ≥ 2% of patients included febrile neutropenia (7%), neutropenia (6%), diarrhea (5%), fatigue and pneumonia (2.3% each). Fatal adverse reactions occurred in 3.2% of patients who received TRODELVY in combination with pembrolizumab including death (unknown cause) (0.9%) and completed suicide, neutropenic sepsis, sepsis, pneumonia, and pulmonary embolism (0.5% each).
Permanent discontinuation of TRODELVY due to an adverse reaction occurred in 7% of patients. Adverse reactions which resulted in permanent discontinuation of TRODELVY in ≥1% of patients included infusion related reaction (0.9%).
Dosage interruptions of TRODELVY due to an adverse reaction occurred in 75% of patients. Adverse reactions which required dosage interruption in ≥5% of patients included neutropenia (44%), upper respiratory tract infection (10%), diarrhea (8%), COVID-19 (6%), and anemia and fatigue (5% each).
Dose reduction of TRODELVY due to an adverse reaction occurred in 35% of patients. Adverse reactions which required dose reductions in ≥5% of patients included neutropenia (15%), diarrhea (8%), and fatigue (6%).
G-CSF was used in 63% of patients who received TRODELVY in combination with pembrolizumab.
The most common (≥25%) adverse reactions, including laboratory abnormalities, were decreased neutrophil count and decreased hemoglobin (86% each), decreased leukocyte count (84%), diarrhea (72%), nausea (68%), decreased lymphocyte count (61%), fatigue (58%), alopecia (52%), increased alkaline phosphatase and increased glucose (50% each), increased alanine aminotransferase (47%), constipation (41%), increased aspartate aminotransferase (40%), rash (37%), decreased potassium (35%), increased lactate dehydrogenase (34%), vomiting (29%), abdominal pain, headache and increased eosinophils (26% each), and decreased albumin (25%).
Tables 5 and 6 summarize the adverse reactions and laboratory abnormalities in ASCENT-04.
Table 5: Adverse Reactions in ≥ 10% of Patients Receiving TRODELVY in Combination with Intravenous Pembrolizumab with Metastatic TNBC in ASCENT-04 | TRODELVY plus pembrolizumab N=221 | Treatment of Physician’s Choice
plus pembrolizumab N=220 |
|---|
| Adverse Reactions
| All Grades (%) | Grade 3-4 (%) | All Grades (%) | Grade 3-4 (%) |
|---|
| Gastrointestinal disorders |
| Diarrhea
| 72 | 12 | 30 | 2.7 |
| Nausea | 68 | 3.2 | 38 | 1.8 |
| Constipation | 41 | 0.5 | 35 | 0.5 |
| Vomiting | 29 | 0.9 | 14 | 1.8 |
| Abdominal Pain
| 26 | 0.5 | 15 | 0 |
| Stomatitis
| 18 | 0.5 | 16 | 0 |
| General disorders and administration site conditions |
| Fatigue
| 58 | 8 | 56 | 3.2 |
| Edema
| 16 | 0.5 | 17 | 0.5 |
| Pyrexia
| 12 | 0.9 | 12 | 0.5 |
| Skin and subcutaneous tissue disorders |
| Alopecia | 52 | 0 | 32 | 0 |
| Rash
| 37 | 1.4 | 33 | 1.8 |
| Pruritus | 14 | 0.5 | 12 | 0.9 |
| Nervous system disorders |
| Headache
| 26 | 0.5 | 18 | 0 |
| Peripheral neuropathy
| 13 | 0.9 | 39 | 4.5 |
| Dizziness
| 12 | 0 | 10 | 0 |
| Musculoskeletal and connective tissue disorders |
| Arthralgia
| 19 | 0.9 | 24 | 0.5 |
| Respiratory, thoracic and mediastinal disorders |
| Cough
| 19 | 0.5 | 20 | 0 |
| Metabolism and nutrition disorders |
| Decreased appetite | 18 | 1.8 | 14 | 0 |
| Hypothyroidism
| 11 | 0.5 | 18 | 0 |
| Infections and infestations |
| Upper respiratory tract infection
| 18 | 0 | 13 | 0 |
| Urinary tract infection
| 16 | 1.4 | 16 | 0.5 |
| COVID-19 | 10 | 0.5 | 7 | 0.5 |
| Reproductive system and breast disorders |
| Breast pain
| 10 | 0 | 9 | 0 |
| Investigations |
| Weight decreased | 10 | 0 | 5 | 0.5 |
Table 6: Laboratory Abnormalities in > 10% of Patients Receiving TRODELVY in Combination with Intravenous Pembrolizumab with Metastatic TNBC in ASCENT-04| Laboratory Abnormality | TRODELVY plus pembrolizumab N=221 | TPC plus pembrolizumab N=220 |
|---|
| All Grades (%) | Grade 3 - 4 (%) | All Grades (%) | Grade 3 - 4 (%) |
|---|
| Hematology | |
| Decreased neutrophil count | 86 | 50 | 86 | 47 |
| Decreased hemoglobin | 86 | 10 | 88 | 18 |
| Decreased leukocytes count | 84 | 32 | 83 | 31 |
| Decreased lymphocyte count | 61 | 21 | 60 | 19 |
| Increased eosinophils | 26 | 0 | 17 | 0 |
| Decreased platelet count | 16 | 5 | 43 | 17 |
| Chemistry | |
| Increased alkaline phosphate | 50 | 0.9 | 33 | 1.8 |
| Increased glucose | 50 | 0 | 47 | 0 |
| Increased alanine aminotransferase | 47 | 4.1 | 55 | 8 |
| Increased aspartate aminotransferase | 40 | 3.7 | 51 | 4.1 |
| Decreased potassium | 35 | 4.6 | 24 | 2.3 |
| Increased lactate dehydrogenase | 34 | 0 | 37 | 0 |
| Decreased albumin | 25 | 0.9 | 14 | 0.9 |
| Decreased sodium | 20 | 1.4 | 20 | 3.2 |
| Increased Urate | 19 | 0 | 7 | 0 |
| Increased magnesium | 17 | 6 | 13 | 3.7 |
| Increased phosphate | 17 | 0 | 12 | 0 |
| Decreased magnesium | 16 | 1.4 | 21 | 0 |
| Increased thyroid stimulating hormone | 15 | 0 | 24 | 0 |
| Decreased phosphate | 14 | 0 | 9 | 0 |
| Increased blood bilirubin | 12 | 3.7 | 8 | 3.2 |
| Increased sodium | 12 | 0.5 | 2.3 | 0.5 |
| Decreased glucose | 11 | 0 | 15 | 1.4 |
| Increased potassium | 11 | 0.9 | 9 | 0.9 |
Previously Treated Locally Advanced or Metastatic TNBC (ASCENT)
The safety of TRODELVY was evaluated in 258 patients with metastatic TNBC who had previously received a taxane and at least two prior chemotherapies and who received at least one dose of TRODELVY 10 mg/kg in ASCENT. [see Clinical Studies (14.1)]. The median duration of treatment was 4.4 months (range: 0 to 23 months).
Serious adverse reactions occurred in 27% of patients receiving TRODELVY. Serious adverse reactions in > 1% of patients receiving TRODELVY included neutropenia (7%), diarrhea (4%), and pneumonia (3%). Fatal adverse reactions occurred in 1.2% of patients who received TRODELVY, including respiratory failure (0.8%) and pneumonia (0.4%).
Permanent discontinuation of TRODELVY due to an adverse reaction occurred in 5% of patients. Adverse reactions which resulted in permanent discontinuation of TRODELVY in ≥1% of patients included pneumonia and fatigue (1% each).
Dosage interruptions of TRODELVY due to an adverse reaction occurred in 63% of patients. Adverse reactions which required dosage interruption in ≥5% of patients included neutropenia (47%), diarrhea (5%), respiratory infection (5%), and leukopenia (5%).
Dose reductions of TRODELVY due to an adverse reaction occurred in 22% of patients. Adverse reactions which required a dose reduction in >4% of patients included neutropenia (11%) and diarrhea (5%).
Granulocyte-colony stimulating factor (G-CSF) was used in 44% of patients who received TRODELVY.
The most common (≥25%) adverse reactions, including laboratory abnormalities, were decreased hemoglobin (94%), decreased lymphocyte count (88%), decrease leukocyte count (86%), decreased neutrophil count (78%), fatigue (65%), diarrhea (59%), nausea (57%), increased glucose (49%), alopecia (47%), constipation (37%), decreased calcium (36%), vomiting, decreased magnesium, and decreased potassium (33% each), increased albumin (32%), abdominal pain (30%), decreased appetite (28%), increased aspartate aminotransferase (27%), increased alanine aminotransferase, increased alkaline phosphatase and decreased phosphate (26% each).
Tables 7 and 8 summarize adverse reactions and laboratory abnormalities, respectively, in ASCENT.
Table 7: Adverse Reactions in ≥ 10% of Patients with Metastatic TNBC in ASCENT | TRODELVY (n=258) | Single Agent Chemotherapy
(n=224) |
|---|
| Adverse Reaction | All Grades % | Grade 3 - 4 % | All Grades % | Grade 3 - 4 % |
|---|
| i. Graded per NCI CTCAE v.5.0. |
| General disorders and administration site conditions |
| Fatigue
| 65 | 6 | 50 | 9 |
| Pyrexia | 15 | 0.4 | 14 | 2.2 |
| Gastrointestinal disorders |
| Diarrhea | 59 | 11 | 17 | 0.9 |
| Nausea | 57 | 3.1 | 26 | 0.4 |
| Vomiting | 33 | 1.6 | 16 | 1.3 |
| Constipation | 37 | 0.4 | 23 | 0 |
| Abdominal Pain | 30 | 2.7 | 12 | 1.3 |
| Stomatitis
| 17 | 1.6 | 13 | 1.3 |
| Skin and subcutaneous tissue disorders |
| Alopecia | 47 | 0 | 16 | 0 |
| Rash | 12 | 0.4 | 5 | 0.4 |
| Pruritus | 10 | 0 | 3.1 | 0 |
| Metabolism and nutrition disorders |
| Decreased appetite | 28 | 1.6 | 21 | 0.9 |
| Respiratory, thoracic and mediastinal disorders |
| Cough | 24 | 0 | 18 | 0.4 |
| Nervous system disorders |
| Headache | 18 | 0.8 | 13 | 0.4 |
| Dizziness | 10 | 0 | 7 | 0 |
| Musculoskeletal and connective tissue disorders |
| Back pain | 16 | 1.2 | 14 | 1.8 |
| Arthralgia | 12 | 0.4 | 7 | 0 |
| Infections and infestations |
| Urinary tract infection | 13 | 0.4 | 8 | 0.4 |
| Upper respiratory tract infection | 12 | 0 | 3.1 | 0 |
| Psychiatric disorders |
| Insomnia | 11 | 0 | 5 | 0 |
Table 8: Laboratory Abnormalities in > 10% of Patients with Metastatic TNBC in ASCENT | Laboratory Abnormality | TRODELVY (n=258) | Single Agent Chemotherapy (n=224) |
|---|
| All Grades (%) | Grade 3 - 4 (%) | All Grades (%) | Grade 3 - 4 (%) |
|---|
| Hematology | |
| Decreased hemoglobin | 94 | 9 | 57 | 6 |
| Decreased lymphocyte count | 88 | 31 | 40 | 24 |
| Decreased leukocyte count | 86 | 41 | 53 | 25 |
| Decreased neutrophil count | 78 | 49 | 48 | 36 |
| Decreased platelet count | 23 | 1.2 | 25 | 2.7 |
| Chemistry | |
| Increased glucose | 49 | 2.3 | 43 | 2.8 |
| Decreased calcium | 36 | 1.6 | 21 | 1.4 |
| Decreased magnesium | 33 | 0.4 | 20 | 0 |
| Decreased potassium | 33 | 4.3 | 28 | 0.9 |
| Increased albumin | 32 | 0.8 | 25 | 1.4 |
| Increased aspartate aminotransferase | 27 | 1.2 | 32 | 1.4 |
| Increased alanine aminotransferase | 26 | 1.2 | 26 | 1.8 |
| Increased alkaline phosphatase | 26 | 0 | 17 | 0.5 |
| Decreased phosphate | 26 | 7.8 | 20 | 3.3 |
| Decreased sodium | 22 | 0.4 | 17 | 0.5 |
| Increased lactate dehydrogenase | 18 | 0 | 22 | 0 |
| Decreased glucose | 10 | 0 | 3.2 | 0 |